Drostanolone Clinical data Trade names Drolban, Masteril, Masteron, others (all as drostanolone propionate) Synonyms Dromostanolone; 2α-Methyl-4,5α-dihydrotestosterone; 2α-Methyl-DHT; 2α-Methyl-5α-androstan-17β-ol-3-one Routes of administration Intramuscular injection (as drostanolone propionate) Drug class Androgen; Anabolic steroid Legal status Legal status
(2 R,5 S,8 R,9 S,10 S,13 S,14 S,17 S)-17-hydroxy- 2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17- tetradecahydrocyclopenta[ a]phenanthren-3-one CAS Number PubChem CID ChemSpider UNII ChEMBL CompTox Dashboard ( EPA) ECHA InfoCard 100.000.334 Chemical and physical data Formula C 20 H 32 O 2 Molar mass 304.46 g/mol g·mol −1 3D model ( JSmol)
(what is this?) (verify)
Drostanolone, or dromostanolone, is an anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which was never marketed.   An  androgen ester prodrug of drostanolone, drostanolone propionate, was formerly used in the treatment of breast cancer in women under brand names such as Drolban, Masteril, and Masteron.    This ester has also been used non-medically for  physique- or performance-enhancing purposes.
Like other AAS, drostanolone is an
agonist of the androgen receptor (AR). It is not a substrate for  5α-reductase and is a poor substrate for 3α-hydroxysteroid dehydrogenase (3α-HSD), and therefore shows a high ratio of anabolic to androgenic activity. As a DHT derivative, drostanolone is not a  substrate for aromatase and hence cannot be aromatized into estrogenic metabolites. While no data are available on the  progestogenic activity of drostanolone, it is thought to have low or no such activity similarly to other DHT derivatives. Since the drug is not  17α-alkylated, it is not known to cause hepatotoxicity.
Drostanolone, also known as 2α-methyl-5α-dihydrotestosterone (2α-methyl-DHT) or as 2α-methyl-5α-androstan-17β-ol-3-one, is a
synthetic androstane steroid and a derivative of DHT.   It is specifically DHT with a  methyl group at the C2α position.  
Drostanolone and its ester
drostanolone propionate were first described in 1959.  Drostanolone propionate was first introduced for medical use in 1961. 
Society and culture
Drostanolone is the generic name of the drug and its , INN , and BAN . DCF  It has also been referred to as  dromostanolone. 
Drostanolone, along with other AAS, is a
schedule III controlled substance in the United States under the Controlled Substances Act.
^ a b c d e f
J. Elks (14 November 2014). . Springer. pp. 652–. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies ISBN . 978-1-4757-2085-3
^ a b c d e f
. Taylor & Francis. January 2000. pp. 377–. Index Nominum 2000: International Drug Directory ISBN . 978-3-88763-075-1
^ a b c d e f g h i j k
William Llewellyn (2011). . Molecular Nutrition Llc. pp. 517–. Anabolics ISBN . 978-0-9828280-1-4
Bennett, MB; Helman, P; Palmer, P (1975). "Hormonal therapy of breast cancer with special reference to Masteril therapy". S. Afr. Med. J. 49: 2036–40. PMID 1242823.
Ringold, H. J.; Batres, E.; Halpern, O.; Necoechea, E. (1959). "Steroids. CV.12-Methyl and 2-Hydroxymethylene-androstane Derivatives". Journal of the American Chemical Society. 81 (2): 427–432. doi: 10.1021/ja01511a040. ISSN 0002-7863.
William Andrew Publishing (22 October 2013). . Elsevier. pp. 1402–. Pharmaceutical Manufacturing Encyclopedia, 3rd Edition ISBN . 978-0-8155-1856-3
Steven B. Karch, MD, FFFLM (21 December 2006). . CRC Press. pp. 30–. Drug Abuse Handbook, Second Edition ISBN . 978-1-4200-0346-8 CS1 maint: multiple names: authors list ( link)